Leerink Swann Comments on Merck & Company, Inc.’s FY2017 Earnings (MRK)
Merck & Company, Inc. (NYSE:MRK) – Leerink Swann raised their FY2017 earnings per share (EPS) estimates for shares of Merck & in a research report issued to clients and investors on Monday. Leerink Swann analyst S. Fernandez now anticipates that the company will earn $3.88 per share for the year, up from their prior forecast of $3.85. Leerink Swann has a “Market Perform” rating and a $70.00 price objective on the stock. Leerink Swann also issued estimates for Merck &’s Q4 2017 earnings at $0.96 EPS, FY2020 earnings at $4.58 EPS and FY2021 earnings at $5.13 EPS.
MRK has been the subject of several other reports. Cowen and Company restated a “hold” rating and set a $70.00 price target on shares of Merck & in a report on Friday, September 1st. Zacks Investment Research cut shares of Merck & from a “buy” rating to a “hold” rating in a report on Wednesday, August 2nd. Jefferies Group LLC restated a “sell” rating and set a $55.00 price target on shares of Merck & in a report on Friday. BMO Capital Markets set a $70.00 price target on shares of Merck & and gave the stock a “buy” rating in a report on Wednesday, October 11th. Finally, Goldman Sachs Group, Inc. (The) restated a “neutral” rating and set a $74.00 price target (up from $70.00) on shares of Merck & in a report on Thursday, July 27th. Two investment analysts have rated the stock with a sell rating, seven have issued a hold rating and eleven have assigned a buy rating to the company’s stock. Merck & has a consensus rating of “Hold” and a consensus target price of $70.67.
TRADEMARK VIOLATION NOTICE: This story was originally posted by American Banking News and is the sole property of of American Banking News. If you are accessing this story on another domain, it was illegally copied and reposted in violation of U.S. and international trademark & copyright law. The correct version of this story can be read at https://www.americanbankingnews.com/2017/10/24/leerink-swann-comments-on-merck-company-inc-s-fy2017-earnings-mrk.html.
Merck & (NYSE:MRK) opened at 63.40 on Tuesday. The stock has a market cap of $172.91 billion, a P/E ratio of 34.33 and a beta of 0.80. Merck & has a 52 week low of $58.29 and a 52 week high of $66.80. The company’s 50 day moving average is $64.55 and its 200 day moving average is $63.71.
Merck & (NYSE:MRK) last released its quarterly earnings data on Friday, July 28th. The company reported $1.01 EPS for the quarter, topping analysts’ consensus estimates of $0.87 by $0.14. The firm had revenue of $9.93 billion for the quarter, compared to the consensus estimate of $9.75 billion. Merck & had a net margin of 17.14% and a return on equity of 26.02%. The firm’s revenue was up .9% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.93 earnings per share.
A number of institutional investors and hedge funds have recently bought and sold shares of the business. Vanguard Group Inc. boosted its stake in shares of Merck & by 1.7% in the 2nd quarter. Vanguard Group Inc. now owns 194,144,317 shares of the company’s stock valued at $12,442,709,000 after purchasing an additional 3,312,459 shares in the last quarter. BlackRock Inc. boosted its stake in shares of Merck & by 1.0% in the 2nd quarter. BlackRock Inc. now owns 184,997,390 shares of the company’s stock valued at $11,856,484,000 after purchasing an additional 1,834,500 shares in the last quarter. Franklin Resources Inc. boosted its stake in shares of Merck & by 3.1% in the 2nd quarter. Franklin Resources Inc. now owns 27,019,572 shares of the company’s stock valued at $1,731,684,000 after purchasing an additional 801,033 shares in the last quarter. Boston Partners boosted its stake in shares of Merck & by 2.6% in the 1st quarter. Boston Partners now owns 19,935,016 shares of the company’s stock valued at $1,266,671,000 after purchasing an additional 500,476 shares in the last quarter. Finally, Legal & General Group Plc boosted its stake in shares of Merck & by 1.3% in the 2nd quarter. Legal & General Group Plc now owns 14,564,388 shares of the company’s stock valued at $933,445,000 after purchasing an additional 192,348 shares in the last quarter. Hedge funds and other institutional investors own 72.86% of the company’s stock.
About Merck &
Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.
Receive News & Ratings for Merck & Company Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Company Inc. and related companies with MarketBeat.com's FREE daily email newsletter.